下跌空間有限?多位基金經理逆市加倉醫藥股
繼蔡嵩鬆管理的諾安成長混合增持卓勝微後,又有基金公司增持上市公司股份至超過5%。
港交所近日公告,截至9月22日,易方達基金持有海吉亞醫療3727.22萬股,持股比例達6.04%。
雖然近期醫藥板塊出現回調,但醫藥股被機構逆勢買入。
易方達大舉增持海吉亞醫療
港交所近日發佈公告顯示,易方達基金分別在9月14日、9月22日買入$海吉亞醫療(06078.HK)$,持股比例超過5%。截至9月14日,易方達基金旗下產品持有海吉亞醫療3097.46萬股,持股比例達5.02%;截至9月22日,易方達基金旗下產品持有海吉亞醫療3727.22萬股,持股比例達6.04%。

海吉亞醫療是易方達基金旗下多位知名基金經理的重倉股。根據基金半年報,截至今年6月底,海吉亞醫療成爲張坤管理的易方達藍籌精選、易方達優質精選等基金前20重倉股,易方達藍籌精選持有海吉亞醫療550萬股,易方達優質精選持有海吉亞醫療200萬股。海吉亞醫療也是陳皓管理的易方達港股通成長、易方達創新未來、易方達均衡成長的前十大重倉股,易方達港股通成長持有海吉亞醫療454萬股,易方達創新未來持有海吉亞醫療423.54萬股,易方達均衡成長持有海吉亞醫療414.08萬股。
海吉亞醫療是以腫瘤科爲核心的醫療集團,建立了覆蓋國內多省市、以腫瘤科爲核心的醫院及放療中心網絡。全資子公司上海伽瑪星科技發展有限公司自主研發生產陀螺旋轉式鈷60立體定向放射治療系統,可用於治療頭部及體部腫瘤。
醫藥板塊下跌空間有限
除了易方達基金加倉海吉亞醫療,還有多位基金經理加倉醫藥股。比如交銀施羅德基金基金經理何帥上半年大幅增加了醫藥股配置。以他管理的交銀阿爾法爲例,Wind統計顯示,該基金截至上半年底,醫療保健板塊的配置比例高達50.33%,而這一數據在2021年底僅爲13.48%。交銀阿爾法的前十大重倉股中,包括長春高新、$藥明康德(02359.HK)$(維權)、金域醫學等多隻醫藥股。
此外,多隻醫藥行業ETF近期份額也有所增長。Wind數據顯示,截至9月23日,易方達滬深300醫藥衛生ETF今年以來份額增加140.12億份,並在9月22日創下歷史新高,達到259.68億份。廣發中證全指醫藥衛生ETF今年以來份額增加32.39億份。
雖然醫藥板塊經歷了一段時間調整,但基金經理對此並不悲觀。諾德基金基金經理朱明睿對醫藥板塊後市持較樂觀態度,認爲目前醫藥板塊下跌空間比較有限。他表示,首先,藥品集採與耗材集採等政策基本落地,在相關上市公司的業績和市值上已得到反映;其次,醫藥板塊中不少公司的基本面依舊呈現高景氣態勢。板塊配置方面,朱明睿比較看好醫藥板塊中的消費醫療、創新器械與科研服務產業鏈三個賽道。
對於醫藥板塊投資機會,泰達宏利基金認爲,在產業技術加速迭代、醫改不斷推進的背景下,國內醫藥企業唯有不斷創新、升級,才能在日益激烈的競爭中笑到最後。在投資決策時,除重點關注一線龍頭外,也可自下而上找尋細分領域的專精特新龍頭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.